[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"parkinson-dis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:parkinson-dis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100641109","longitudinal-natural-history-protocol-for-prkn--and-pink1-linked-pd-100641109",false,"NCT07613112","Longitudinal Natural History Protocol for PRKN- and PINK1-Linked PD","Longitudinal Natural History Protocol for PRKN- and PINK1-linked PD","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\nAll participants:\n\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female between the ages of 18-80 years old\n* Ability of subject to understand and the willingness to sign an informed consent document\n* Ability of subject to travel to the NIH Clinical Center\n\nAdditional inclusion criteria for each cohort as below:\n\nPD Mito - Biallelic:\n\n* Established clinical diagnosis of Parkinson's disease\n* Two Pathogenic or likely pathogenic variants in PRKN or PINK1\n\nPD Mito - Monoallelic:\n\n* Established clinical diagnosis of Parkinson's disease\n* One Pathogenic or likely pathogenic variant in PRKN and\u002For PINK1\n\nIdiopathic Parkinson's Disease (PD):\n\n* Established clinical diagnosis of Parkinson's disease\n* Etiology of PD is idiopathic\u002Fsporadic based on investigator determination\n\nNon-manifesting mito:\n\n* One or two pathogenic or likely pathogenic variant in PRKN and\u002For PINK1\n* Lack of clinical diagnosis of Parkinson's disease\n* Lack of current or clinically significant neurological disorder (based on investigator determination)\n\nHealthy Volunteer\n\n-Lack of current or clinically significant neurological disorder (based on investigator determination)\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\nAll participants:\n\n* Symptomatic PD syndromes due to drugs (e.g., metoclopramide, flunarizine, neuroleptics), metabolic disorders (e.g., Wilson's disease hypothyroidism), encephalitis, brain lesion, atypical parkinsonism, other monogenic forms of PD (e.g., GBA1, LRRK2, SNCA, VPS35, CHCHD2, DJ1, ATP13A2) other genetic disorders that may cause parkinsonism (e.g., spinocerebellar ataxia, X-linked dystonia parkinsonism)\n* Pregnancy at time of study enrollment\n* Any other reason that, in the opinion of the investigator, would render the participant unsuitable for study enrollment\n* Unwilling to allow samples or data to be shared with other researchers or institutions.\n* NIH staff or family members of study team members\n\nHealthy Volunteer:\n\n-Participants who become pregnant during the study will be withdrawn from further study procedures at the time pregnancy is identified.\n\nProcedural Exclusions:\n\nSubjects may still be enrolled if they cannot participate in certain procedures due to not meeting the inclusion requirements for that specific procedure. Subjects who meet exclusion criteria for procedures listed below may still undergo the procedure at a later time if the reason of exclusion is no longer present.\n\nBrain MRI:\n\n* Contraindications to MRI such as a contraindicated non-removable metal device (i.e., pacemaker, defibrillator, insulin pump, metal clips, non-removable jewelry)\n* Pregnancy\n\nAccelerometer:\n\n-Non ambulatory\n\nLumbar puncture procedure:\n\n* PT\u002FPTT values that are prolonged greater than or equal to 3 seconds from the upper limit of normal (including treatment with oral and parenteral anticoagulants)\n* INR greater than 1.4, thrombocytopenia (\\\u003C70,000), or abnormal bleeding time or platelet dysfunction\n* History of a bleeding disorder\n* Use of anticoagulants or antiplatelets\n* Pregnancy\n* History of headache requiring blood patch after a previous LP\n\nNeedle muscle biopsy:\n\n* PT\u002FPTT values that are prolonged greater than or equal to 3 seconds from the upper limit of normal (including treatment with oral and parenteral anticoagulants)\n* INR greater than 1.4, thrombocytopenia (\\\u003C70,000), or abnormal bleeding time or platelet dysfunction\n* History of a bleeding disorder\n* Use of anticoagulants or antiplatelets\n* Pregnancy","ALL","18 Years","100 Years",{"count":20,"type":21},70,"ESTIMATED","OBSERVATIONAL","Background:\n\nParkinson s disease is a neurologic disorder that affects movement. Its cause is unknown, and it usually begins later in life. Gene changes (PRKN and PINK1) can also cause rare types of Parkinson s disease that start at a young age. Researchers want to conduct a natural history study to learn more about how genes play a role in Parkinson s disease.\n\nObjective:\n\nTo collect data and biological samples from people with different types of Parkinson s disease.\n\nEligibility:\n\nPeople aged 18 to 80 years with either Parkinson s disease or PRKN- and PINK1-linked Parkinson s disease. Healthy volunteers are also needed.\n\nDesign:\n\nParticipants will have 6 clinic visits over 5 years. Each visit may take 1 to 3 days.\n\nDuring each visit:\n\nParticipants will have a physical exam. The exam will be videotaped.\n\nThey will answer questions about their movement, thinking, mood, and sense of smell. The extent of any symptoms of Parkinson s disease will be evaluated: Participants movements may be assessed with a finger tapping test. They may be asked to scratch and sniff different scented strips to identify odors.\n\nThey will wear motion sensors on their arms, legs, chest, and back at the clinic. They will wear motion sensor devices on their wrists at home for 1 week.\n\nBlood and urine samples will be collected.\n\nOther tests are optional:\n\nMagnetic resonance imaging (MRI) scan of the brain. Participants will lie on a table that slides into a tube.\n\nLumbar puncture (spinal tap). A thin needle will be inserted into their lower back to draw out a sample of the fluid around their spinal cord.\n\nMuscle biopsy. A small sample of tissue will be taken from the leg.",[25],"PARKINSON DIS",[27,28,29],"PINK1","PRKN","PARKINSON","NOT_YET_RECRUITING","2026-08-12",{"date":33,"type":34},"2026-08-13","ACTUAL",{"date":36,"type":21},"2026-10-01",{"date":38,"type":21},"2036-05-30",{"name":40,"class":41},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":42},"100650239","comparative-study-of-tis-efficacy-across-different-targets-100650239","NCT07745673","Comparative Study of TIS Efficacy Across Different Targets","Comparative Efficacy of Temporal Interference Stimulation at Different Targets in Parkinson's Disease","tTIS","Inclusion Criteria:\n\n1. Adult males or females aged ≥40 years;\n2. Diagnosis of idiopathic Parkinson's disease according to the UK Brain Bank criteria, with age of onset ≥40 years;\n3. Previous or current treatment with dopamine replacement therapy (e.g., levodopa) with good response;\n4. Hoehn and Yahr (H\\&Y) stage 1.5-2.5;\n5. Able to walk independently for at least 5 minutes without assistive devices;\n6. No severe freezing of gait (FOG);\n7. Disease duration ≥2 years since diagnosis, clinically stable, and able to comply with study assessments and interventions;\n8. Stable medication regimen for at least 4 weeks prior to the study;\n9. Signed informed consent form; subject or legal guardian is able to understand and willing to participate in this study.\n\nExclusion Criteria:\n\n1. Presence of other neurological disorders that may affect the study (e.g., ...);\n2. Mild cognitive impairment or above (MoCA ≤23);\n3. Orthopedic or other medical conditions that may affect gait or balance;\n4. Contraindications to MRI, such as claustrophobia;\n5. History of antipsychotic, antidepressant, or other medications that may affect dopamine levels;\n6. History of other severe psychiatric disorders;\n7. History of epilepsy, traumatic brain injury, or implanted metallic devices in the brain or heart (e.g., stimulators, pacemakers) or other contraindications;\n8. History of electroconvulsive therapy (ECT);\n9. Currently participating in other gait- or balance-related intervention training;\n10. Physician-diagnosed cardiovascular risk factors for exercise.","40 Years",{"count":53,"type":21},18,"INTERVENTIONAL",[56],"NA","This prospective, randomized, participant- and outcome-assessor-blinded, parallel-group exploratory trial will compare the target-dependent clinical, neuroimaging, and electrophysiological effects of temporal interference stimulation (TIS) targeting the subthalamic nucleus (STN) or globus pallidus internus (GPi) in patients with Parkinson's disease (PD).\n\nEighteen participants with idiopathic PD will be randomly assigned in a 1:1 ratio to the STN-TIS or GPi-TIS group. Participants will receive one 20-minute TIS session daily for 7 consecutive days. Motor symptoms will be assessed using the MDS-UPDRS Part III immediately before and after each daily stimulation session. Resting-state functional magnetic resonance imaging (fMRI) and 64-channel electroencephalography (EEG) will be performed before the first stimulation session and immediately after completion of the 7-day intervention.\n\nThe primary outcomes are: (1) change in MDS-UPDRS Part III score from Day 1 before stimulation to Day 7 after stimulation; and (2) changes in regional spontaneous brain activity and seed-based functional connectivity measured using resting-state fMRI. Secondary outcomes are: (1) daily immediate changes in MDS-UPDRS Part III scores and the proportion of participants achieving at least 30% improvement at Day 7; and (2) changes in resting-state 64-channel EEG relative bandpower.\n\nSafety and tolerability will be evaluated by monitoring adverse events and local skin reactions throughout the intervention. This study aims to provide preliminary evidence regarding target-dependent functional response patterns associated with STN- and GPi-targeted TIS in PD.",[25],[60,61,62,63],"Temporal Interference Stimulation","Parkinson's disease","Non-invasive deep brain stimulation","Randomized controlled trial","RECRUITING","2026-07-29",{"date":67,"type":34},"2026-08-04",{"date":69,"type":34},"2026-06-29",{"date":71,"type":21},"2027-12-31",{"name":73,"class":74},"Zhongnan Hospital","OTHER",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":54,"phases":86,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":42},"100646678","mobile-application-for-gait-training-in-parkinsons-disease-100646678","NCT07687979","Mobile Application for Gait Training in Parkinson's Disease","Development and Investigation of the Effectiveness of an External Stimulus-Supported Gait Training Mobile Application for Patients With Parkinson's Disease","Inclusion Criteria:\n\nDiagnosed with idiopathic Parkinson's disease by a neurologist based on clinical and radiological findings.\n\nDisease severity between stages 1 to 3 according to the Modified Hoehn and Yahr Scale.\n\nAble to walk at least 10 meters independently or with an assistive device.\n\nBeing in the \"ON\" period of Parkinson's medication.\n\nAbility to use technological devices such as smartphones (scoring 35 or higher on the Digital Competence Inventory for Older Adults).\n\nFluent in reading, understanding, and speaking Turkish.\n\nVoluntarily participating in the study.\n\nExclusion Criteria:\n\nHaving neurological disorders other than Parkinson's disease that could affect mobility.\n\nHistory of knee joint surgery or traumatic injury affecting the knee joint.\n\nHistory of any surgery within the last 6 months.\n\nPresence of a deep brain stimulator.\n\nHearing impairment.\n\nCognitive impairment or inability to understand and follow the study procedures.\n\nOther physical or systemic conditions that could affect walking assessments (e.g., amputation, severe diabetes mellitus, alcohol addiction).","60 Years","80 Years",{"count":85,"type":21},52,[56],"The developed mobile application provides patient-specific metronome-based auditory cues and simultaneous tactile vibrations to regulate walking rhythm. In this study, the effects of the mobile application on walking performance and balance in patients with Parkinson's disease will be examined in a single-center, controlled design. Participants will undergo gait training for 30 minutes per day, 3 days a week, for a total of 6 weeks. The experimental group will use the mobile application, while the control group will receive standard gait training without any external stimuli. Walking and functional performance will be assessed before and after the intervention using the Timed Up and Go Test (TUG) to assess functional mobility and dynamic balance, the 5-Times Sit to Stand Test (5xSST) to evaluate lower extremity functional strength, and the Freezing of Gait Questionnaire (FOGQ) to evaluate freezing episodes. Additionally, spatiotemporal walking parameters will be measured using a separate gait analysis mobile application. Appropriate statistical tests will be applied, and a significance level of p\\\u003C0.05 will be considered.",[25],[90,91,92,93,94,95,96,97],"Gait Training","Freezing of Gait","Mobile Application","External Cues","Rhythmic Auditory Stimulation","Tactile Stimulation","Rehabilitation","Metronome","2026-07-02",{"date":100,"type":34},"2026-07-07",{"date":102,"type":34},"2026-04-07",{"date":104,"type":21},"2026-09",{"name":106,"class":74},"Ege University"]